{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:53:09Z","timestamp":1787961189052,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"DOI":"10.7759\/cureus.23463","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T20:51:30Z","timestamp":1648155090000},"source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of Self-Reported Muscle Pain Among Statin Users From National Guard Hospital, Riyadh"],"prefix":"10.7759","author":[{"given":"Ihab","family":"Suliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Batarfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Almohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Aljeraisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Alnaserallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.17226\/12940","article-title":"Cardiovascular disability. Washington, DC: National Acad","author":"Institute of Medicine (US) Committee on Social Security Cardiovascular Disability Criteria","year":"2010","unstructured":"Institute of Medicine (US) Committee on Social Security Cardiovascular Disability Criteria. Cardiovascular Disability: Updating the Social Security Listings. National Academies Press (US), Washington, DC; 2010. 10.17226\/12940"},{"key":"ref2","unstructured":"NationaI Heart, Lung and Blood Institute. Coronary heart disease. (2022). Accessed. 22 March 2022: https:\/\/www.nhlbi.nih.gov\/health-topics\/ischemic-heart-disease."},{"key":"ref3","article-title":"Pharmacology for health professionals, 2nd ed","author":"Acosta WR","year":"2013","unstructured":"Acosta WR, Roach, S. Pharmacology for health professionals, 2nd ed. Wolters Kluwer\/Lippincott Williams & Wilkins Health, Philadelphia; 2013."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22205","article-title":"Prevalence and risk factors of muscle complications secondary to statins","volume":"44","author":"El-Salem K","year":"2011","unstructured":"El-Salem K, Ababneh B, Rudnicki S, et al.. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011, 44:877-81. 10.1002\/mus.22205","journal-title":"Muscle Nerve"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-017-0259-7","article-title":"Management of statin intolerance in 2018: still more questions than answers","volume":"18","author":"Toth PP","year":"2018","unstructured":"Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018, 18:157-73. 10.1007\/s40256-017-0259-7","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd TT","year":"2011","unstructured":"Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011, 10:373-87. 10.1517\/14740338.2011.540568","journal-title":"Expert Opin Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients","volume":"29","author":"Nichols GA","year":"2007","unstructured":"Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007, 29:1761-70. 10.1016\/j.clinthera.2007.08.022","journal-title":"Clin Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3138\/ptc.2012-65","article-title":"Statin-induced rhabdomyolysis: a comprehensive review of case reports","volume":"66","author":"Mendes P","year":"2014","unstructured":"Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can. 2014, 66:124-32. 10.3138\/ptc.2012-65","journal-title":"Physiother Can"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes ES","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al.. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015, 36:1012-22. 10.1093\/eurheartj\/ehv043","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2012.01.004","article-title":"Statin induced myotoxicity","volume":"23","author":"Sathasivam S","year":"2012","unstructured":"Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012, 23:317-24. 10.1016\/j.ejim.2012.01.004","journal-title":"Eur J Intern Med"},{"key":"ref11","article-title":"Basic & Clinical Pharmacology, 12th edition","author":"Katzung BG","year":"2012","unstructured":"Katzung BG, Masters SB, Trevor AJ (eds). Basic & Clinical Pharmacology, 12th edition. McGraw-Hill Medical, New York; 2012."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.11","article-title":"Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions","volume":"13","author":"Feng Q","year":"2012","unstructured":"Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics. 2012, 13:579-94. 10.2217\/pgs.12.11","journal-title":"Pharmacogenomics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak A","year":"2010","unstructured":"Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010, 210:337-43. 10.1016\/j.atherosclerosis.2009.11.033","journal-title":"Atherosclerosis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link E","year":"2008","unstructured":"Link E, Parish S, Armitage J, et al.. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008, 359:789-99. 10.1056\/NEJMoa0801936","journal-title":"N Engl J Med"},{"key":"ref15","article-title":"Prevalence of myopathy in subjects on statin therapy attending the National Center for Diabetes, Endocrinology, and Genetics in Jordan","volume":"4","author":"Khlief Y","year":"2015","unstructured":"Khlief Y, Hyassat D, Liswi M, Jaddou H, Ajlouni K. Prevalence of myopathy in subjects on statin therapy attending the National Center for Diabetes, Endocrinology, and Genetics in Jordan. Endocrinol Metab Syndr. 2015, 4:1000204.","journal-title":"Endocrinol Metab Syndr"},{"key":"ref16","article-title":"Prevalence of statin induced myopathy in Lahore, Pakistan","volume":"31","author":"Sadeeqa S","year":"2018","unstructured":"Sadeeqa S, Maqsood M, Ahmad M. Prevalence of statin induced myopathy in Lahore, Pakistan. Pak J Pharm Sci. 2018, 31:617-22.","journal-title":"Pak J Pharm Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-016-0211-y","article-title":"Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)\u00a9","volume":"10","author":"Jacobson TA","year":"2017","unstructured":"Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH. Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)\u00a9. Patient. 2017, 10:321-34. 10.1007\/s40271-016-0211-y","journal-title":"Patient"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb BA","year":"2008","unstructured":"Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008, 8:373-418. 10.2165\/0129784-200808060-00004","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/89108-prevalence-of-self-reported-muscle-pain-among-statin-users-from-national-guard-hospital-riyadh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:05Z","timestamp":1707507785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/89108-prevalence-of-self-reported-muscle-pain-among-statin-users-from-national-guard-hospital-riyadh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.23463","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}